These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16287616)

  • 21. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
    Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Which is the best anticoagulant for whole blood aggregometry platelet function testing? Comparison of six anticoagulants and diverse storage conditions.
    Kaiser AF; Neubauer H; Franken CC; Krüger JC; Mügge A; Meves SH
    Platelets; 2012; 23(5):359-67. PubMed ID: 21999185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Li W; Fu X; Xue H; Wang Y; Wang X; Zhao Y; Geng W; Yang Z; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiovasc Ther; 2013 Aug; 31(4):210-4. PubMed ID: 22954393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Manjappa N; Cavusoglu E
    J Invasive Cardiol; 2008 Feb; 20(2):53-8. PubMed ID: 18252967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
    Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
    J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of platelet function in dogs using a novel impedance aggregometer.
    Kalbantner K; Baumgarten A; Mischke R
    Vet J; 2010 Aug; 185(2):144-51. PubMed ID: 19879171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of alcohol withdrawal on responses of platelets from alcoholics--a study using platelet-rich plasma from blood anticoagulated with D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH2Cl).
    Rand ML; Neiman J; Jakowec DM; Packham MA
    Thromb Haemost; 1990 Apr; 63(2):178-82. PubMed ID: 2363118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
    Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
    J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
    Danzi GB; Sesana M; Capuano C; Mauri L; Predolini S; Baglini R
    Int J Cardiol; 2006 Feb; 107(2):241-6. PubMed ID: 16412804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration.
    Tucci MA; Ganter MT; Hamiel CR; Klaghofer R; Zollinger A; Hofer CK
    J Thorac Cardiovasc Surg; 2006 Jun; 131(6):1314-22. PubMed ID: 16733164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].
    Barbou F; Frère C; Hovasse T; Cuisset T; Said LN; Quilici J; Alessi MC; Bonnet JL
    Arch Mal Coeur Vaiss; 2006 Oct; 99(10):894-9. PubMed ID: 17100140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability in platelet responses to collagen--comparison between whole blood perfusions, traditional platelet function tests and PFA-100.
    Lepäntalo A; Beer JH; Siljander P; Syrjälä M; Lassila R
    Thromb Res; 2001 Jul; 103(2):123-33. PubMed ID: 11457470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
    Danzi GB; Capuano C; Sesana M; Mauri L; Sozzi FB
    Am J Cardiol; 2006 Feb; 97(4):489-93. PubMed ID: 16461043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
    Siotia A; Buckland R; Judge HM; Sastry P; Storey RF
    Thromb Haemost; 2006 Jun; 95(6):997-1002. PubMed ID: 16732379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change.
    Greco NJ; Tenner TE; Tandon NN; Jamieson GA
    Blood; 1990 May; 75(10):1989-90. PubMed ID: 2337670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
    Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.